A Phase II Study of CLR 131 in People with Central Nervous System Lymphoma


Full Title

An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)


The purpose of this study is to evaluate the safety and effectiveness of the investigational treatment CLR 131 in people with lymphoma of the brain or spinal cord (central nervous system or CNS lymphoma) that has come back or continued to grow despite treatment. CLR 131 is a targeted form of radiotherapy that gives off cancer-killing doses of radiation to tumor tissue while limiting the effects of radiation on normal tissue and organs near the tumor. It is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have CNS lymphoma that came back or continued to grow despite treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Christian Grommes at 212-610-0344.




Phase II (phase 2)


ClinicalTrials.gov ID